Deutsche Bank analyst Emmanuel Papadakis downgraded Roche to Sell from Hold with a price target of CHF 265, down from CHF 300.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
- Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover
- Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
- Roche announces EC approval of Xofluza in children aged one year and above
- Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above